Literature DB >> 25417063

Chondrogenic and Osteogenic Induction from iPS Cells.

Ji-Yun Ko1, Gun-Il Im2.   

Abstract

Articular cartilage (AC) does not heal spontaneously when injured in adults. This incapacity for self-repair after damage ultimately leads to the development of osteoarthritis. In contrast, bone repairs itself without scarring. However, complete bone healing fails to occur in large defects coming from major trauma or malignant tumor resection. Cell therapy has been investigated for these musculoskeletal conditions. Induced pluripotent stem cells (iPSCs) possess the characteristics of embryonic stem cells (ESCs) in potentially unlimited proliferation while avoiding the ethical controversies. However, several issues need to be resolved before iPSCs can be considered as a potential therapeutic measure for cartilage and bone regeneration. The authors developed protocol to examine the in vitro chondrogenesis and osteogenesis from hiPSCs and in vivo cartilage and bone regeneration using animal models.

Entities:  

Keywords:  Cell therapy; Chondrogenesis; Induced pluripotent stem cells; Osteogenesis; Regeneration

Mesh:

Substances:

Year:  2016        PMID: 25417063     DOI: 10.1007/7651_2014_136

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Patient-Derived Human Induced Pluripotent Stem Cells From Gingival Fibroblasts Composited With Defined Nanohydroxyapatite/Chitosan/Gelatin Porous Scaffolds as Potential Bone Graft Substitutes.

Authors:  Jun Ji; Xin Tong; Xiaofeng Huang; Junfeng Zhang; Haiyan Qin; Qingang Hu
Journal:  Stem Cells Transl Med       Date:  2015-11-19       Impact factor: 6.940

Review 2.  Repair of Damaged Articular Cartilage: Current Approaches and Future Directions.

Authors:  Ekaterina V Medvedeva; Ekaterina A Grebenik; Svetlana N Gornostaeva; Vladimir I Telpuhov; Aleksey V Lychagin; Peter S Timashev; Andrei S Chagin
Journal:  Int J Mol Sci       Date:  2018-08-11       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.